Sudden chest pain, breathlessness, coughing up blood, one sided leg swelling or pain, facial droop, slurred speech, sudden weakness or sudden vision loss need emergency care now. Call 911.
Antithrombin is a protein made mainly in the liver that switches off the enzymes that drive clot formation, above all thrombin and factor Xa 1. It belongs to a family of proteins called serpins, which work by acting as decoys. The clotting enzyme attacks antithrombin as though it were an ordinary target, becomes locked into a complex it cannot escape, and the pair is then cleared from circulation 1. One molecule of antithrombin removes one clotting enzyme permanently.
On its own, that reaction is slow. It speeds up enormously when antithrombin binds the sugar like molecules that coat the inner lining of healthy blood vessels, which concentrates the brake exactly where blood meets a vessel wall 1. The practical effect is that clotting stays local. A cut seals, while blood a few centimetres away keeps flowing.
This is worth holding onto, because it explains why antithrombin sits in a different category from most clotting markers. Fibrinogen, platelets and the clotting factors are the accelerator. Antithrombin, along with protein C and protein S, is part of the braking system. Most routine panels measure the accelerator and say nothing about the brake, which is why a standard clotting screen can look entirely ordinary while antithrombin activity is low. A test has to ask the question directly to get an answer.
Because antithrombin restrains the final common step of coagulation, a shortfall affects clot formation broadly rather than in one narrow pathway. Research suggests that antithrombin deficiency is associated with a substantially increased risk of venous thrombosis compared with people who have normal activity 2. Clinically it is described as a high risk thrombophilia rather than a mild one 3.
That matters for how a result is read. Several inherited clotting tendencies are common and carry a modest effect each. Antithrombin deficiency runs the other way. It is uncommon, and when it is present the implication for an individual is larger, which is why it usually prompts a fuller conversation about personal history, family history and situations that add temporary risk such as surgery, immobility, injury or long travel 4.
It is also easy to miss. Research suggests that antithrombin deficiency remains underdiagnosed, partly because routine clotting tests do not detect it and partly because a low value can be dismissed when it appears during an acute illness 3.
None of this means that a low result predicts a clot. Plenty of people with reduced activity never have one, and most clots happen in people with completely normal antithrombin. The finding shifts probability, it does not decide an outcome. What it does is give a clinician better information when weighing risk around surgery, prolonged immobility or a family history of unexplained clots.
The standard test measures function, not quantity. A functional activity assay asks how much clotting enzyme a sample of your plasma can switch off, and reports the answer as a percentage of normal activity. Guidance for clinical laboratory testing recommends a functional activity assay as the first line test, because it detects both a shortage of protein and a protein that is present but working poorly 5.
A second test, the antigen assay, measures how much antithrombin protein is physically present. It is not a first line test. Its job is to sort out a low activity result 5. When both activity and antigen are low, there is simply less of a normal protein. When activity is low but antigen is normal, there is enough protein but it is not doing its job properly.
That distinction has a name. Reduced quantity is called type I deficiency and reduced function with normal quantity is called type II, with type II further divided according to which part of the molecule is affected, the region that attacks the clotting enzyme, the region that accelerates the reaction at the vessel wall, or changes that affect more than one region at once 6.
Genetic testing is a third layer. Variants in the SERPINC1 gene underlie inherited antithrombin deficiency, and the inheritance pattern is typically autosomal dominant, meaning a single altered copy is enough to lower activity 6. Whether genetic testing is useful in a given case is a clinician's call, not something a lab number decides on its own.
Antithrombin results are reported as a percentage of normal activity, and most adult reference ranges sit somewhere near 80 to 120 percent, with the exact cut-offs differing by laboratory and assay.
| Measure | What it reports | Typical adult reference range | How labs regard it |
|---|---|---|---|
| Antithrombin activity (functional assay) | How well the protein works | Commonly around 80 to 120 percent of normal | First line test; the low end is what matters |
| Antithrombin antigen (immunologic assay) | How much protein is present | Commonly around 80 to 120 percent of normal | Used after a low activity result, to separate type I from type II |
These are typical laboratory reference ranges, not diagnostic verdicts, and they vary by laboratory, assay method, age and sex. Newborns and young infants normally run lower than adults, which is why paediatric results are read against age specific ranges. Always compare your number with the reference range printed on your own report rather than one from the internet, because two labs using different methods can report the same sample differently.
No FitScript optimal range is supplied for antithrombin, so this marker is read against the reporting laboratory's own reference range. A result slightly below the lower limit is better described as suboptimal or outside the standard range than as abnormal in any final sense, because the next step is almost always a repeat test rather than a conclusion.
A low result means your plasma switched off less clotting enzyme than expected in the assay, and that single fact has several possible explanations. The useful sequence is observation, then possible meaning, then next step.
The observation is a number below the lab's lower limit. The possible meanings fall into two broad groups. The first is inherited deficiency, where a variant in SERPINC1 lowers either the amount or the quality of the protein from birth 6. The second, and more common, is acquired deficiency, where something is consuming the protein, reducing its production or losing it from the body 3.
The depth of the drop gives some information but not a diagnosis. Mildly reduced activity on one sample is often reproducible as normal on a second, while a clearly reduced value that persists on repeat testing in an unprovoked setting raises the question of an inherited cause more seriously 4.
The next step is never self-interpretation. A low antithrombin result is worth discussing with a clinician, who will look at when the sample was drawn, what else was happening at the time, your personal clot history, your family history and the rest of your coagulation results before deciding whether a repeat test, an antigen assay or a referral makes sense. A low value on its own does not mean you have a clotting disorder, and it does not mean a clot is coming.
Results above the reference range are not generally used as a risk marker, and laboratories regard the antithrombin test mainly as a way to detect low activity. A single high reading usually says more about assay variation, sample handling or the specific method used than about your physiology.
There is one practical consequence of a value sitting comfortably in the upper half of the range. It makes inherited deficiency unlikely, which is often the reason the test was ordered in the first place. A clear normal or high result answers that question, and attention usually moves to other explanations for whatever prompted testing.
What a high result does not do is cancel out other risk. Antithrombin is one brake among several, and a normal brake does not rule out a problem with the accelerator, with platelets, with a vessel wall or with an acquired condition that promotes clotting. Read the result as the answer to one specific question rather than as a clean bill of health for clotting as a whole.
Acquired causes are the usual explanation for a low value, and they tend to fall into four groups 3.
Reduced production is the first. Antithrombin is made mainly in the liver, so significant liver disease lowers the supply 1. Severe malnutrition can do the same by limiting the raw material for protein synthesis.
Loss is the second. Antithrombin is a relatively small protein, so when kidneys leak protein into the urine, antithrombin leaves with it. Large protein losses through the gut can act the same way.
Consumption is the third, and it is the one that most often confuses a result. An active clot, widespread activation of clotting during severe infection, major trauma or major surgery all use antithrombin up faster than the liver replaces it. The level falls because the system is working hard, not because it was built short.
Physiological and treatment related shifts make up the fourth group. Antithrombin activity changes across pregnancy and in the period after delivery, and certain blood thinners alter measured activity because of how they interact with the protein in the assay, which is why recommendations address the timing of testing relative to blood thinner use 5. Acute illness of almost any kind can nudge the number down temporarily.
This list is the reason a clinician asks what was happening on the day of the draw. A result taken in hospital during a serious illness carries far less information about inherited risk than the same number taken months later when you are well. Nothing here is a reason to change or stop any medication on your own. Treatment decisions belong to a licensed provider.
Yes. Studies suggest that some people show a transient antithrombin deficiency, with activity measured low at one point and normal at another, which is a strong argument against acting on a single value 7.
That finding fits what the acquired causes already predict. If clotting activation, illness, liver stress or protein loss can pull the number down, then the number should rise again when the trigger resolves. The practical implication is that a low result is a prompt to retest under calmer conditions rather than a label.
Timing also matters for a different reason. People are most often tested in exactly the circumstances that distort the result, meaning during or shortly after a clotting event, during a hospital admission or while on blood thinners. Testing when you are well, not acutely ill and not in the immediate aftermath of an event gives a far more interpretable number 5.
So if you are handed a low antithrombin value, the two questions worth asking a clinician are simple. What else was happening when this sample was taken, and when would a repeat test be most informative. A clinician decides both, and the answer frequently is that a second sample weeks or months later settles the matter.
The test is a standard venous blood draw into a tube containing an anticoagulant preservative, after which the plasma is separated and run on a functional assay. There is no special preparation and fasting is not generally required, though your lab or clinician may give specific instructions.
Reliability depends less on what you do beforehand than on when the sample is taken and how the result is confirmed. Recommendations for laboratory testing emphasise a functional activity assay as the starting point, confirmation of a low value on a separate sample, and the use of an antigen assay to classify a confirmed low activity result 5. A single out of range value is a signal to repeat, not a conclusion.
Sample handling matters too. Plasma that sits too long before processing, a short draw into the tube, or a difficult collection can all nudge coagulation assays off. If a result looks out of keeping with everything else, a redraw is a reasonable first step.
The other variable is the assay itself. Different methods are not perfectly interchangeable, so a borderline value measured on one platform may read slightly differently on another. This is one reason to compare results against the same laboratory's range over time rather than mixing reports from different providers and reading the difference as a real change in your biology.
Finally, context is part of the test. A clinician interpreting antithrombin wants the clinical picture alongside the number, including recent illness, surgery, medications and family history. A result read in isolation is a number without a question attached to it.
Because both situations change the measurement itself, not just the risk. During an active clot, antithrombin is being consumed as it does its job, so activity can read low simply because the system is in use. Testing in that window can produce a low value in someone whose baseline is entirely normal, which is one reason recommendations address when testing should and should not be performed 5.
Blood thinners add a second distortion. Some of them work through or alongside antithrombin, so measured activity can shift while the drug is on board, again in a way that says nothing about your inherited baseline 5. A result drawn under those conditions cannot cleanly separate inherited deficiency from the effect of the therapy.
The mirror image is also true. A result taken during acute illness may look falsely reassuring in some circumstances, so neither direction of error is safe to assume.
What this does not mean is that you should pause, delay or stop any blood thinner in order to get a cleaner test. That decision carries its own risk and belongs entirely to the prescribing clinician, who will judge whether testing is worth doing at all, when it should happen and what it would change. In many cases the useful plan is to defer testing until a stable, well period, and in others the result would not alter management enough to justify the exercise. Either way, a clinician decides, and treatment decisions belong to a licensed provider.
Antithrombin deficiency is uncommon overall, and research suggests it is found more often among people investigated after a thrombosis and in families with clustered clotting than in unselected populations 8. That is the pattern you would expect from a rare finding with a meaningful effect on risk.
Family history also runs in the other direction. When a deficiency is confirmed in one person, relatives may be considered for testing, because an autosomal dominant pattern means first degree relatives have a meaningful chance of sharing it. Whether and when to test a relative, including timing and counselling, is a clinician led decision rather than something to arrange from a single report.
It appears to change their structure, not only their likelihood. Antithrombin deficiency is associated with a prothrombotic plasma fibrin clot phenotype, meaning clots that form in a denser, less permeable arrangement and are less readily broken down 9.
That is a useful idea to hold alongside the risk numbers. A shortfall in braking capacity lets more thrombin be generated, and the amount of thrombin present while a clot forms influences how tightly the fibrin mesh is woven. A tighter mesh resists the body's own clot dissolving machinery for longer.
It also connects antithrombin to the rest of a coagulation picture. Fibrinogen supplies the raw material for that mesh, platelets supply the scaffold, and the natural brakes set how aggressively the process runs. Looking at one marker tells you about one input. Looking at several together tells you more about how the system behaves, which is why clotting markers are usually interpreted as a group rather than one line at a time.
Antithrombin is most informative inside a panel, because almost every alternative explanation for a low value is visible in another marker. The usual companions fall into four groups.
The other natural brakes come first. Protein C activity and protein S activity sit in the same system, and they are typically assessed together when inherited clotting tendency is the question. Inherited variants such as factor V Leiden and the prothrombin gene variant are usually considered in the same conversation.
General clotting tests come second. A complete blood count with platelet count, prothrombin time and activated partial thromboplastin time describe the broad state of coagulation, and D-dimer reflects whether clot breakdown products are elevated at the moment of testing.
Organ markers come third, because they explain acquired deficiency. Liver markers such as albumin, ALT and AST speak to production capacity, since antithrombin is made mainly in the liver. A urine albumin to creatinine ratio speaks to protein loss through the kidneys.
Inflammation markers come fourth. High sensitivity CRP gives context on whether an acute process was underway when the sample was drawn, which matters because illness can temporarily lower antithrombin activity.
This is the argument for breadth over single tests. A membership like FitScript covers 150+ biomarkers tested per year, and Atlas, the AI health advisor, reads those markers together so that a single out of range value is interpreted against the rest of your results rather than on its own. Any clinical decision that follows is still made by a licensed provider.
Fibrinogen is the protein that forms the physical mesh of a clot, so it sits on the accelerator side of the same system that antithrombin restrains. It is commonly measured alongside the natural anticoagulants because the two together describe both how readily a clot forms and how firmly it is held in check.
FitScript's optimal range for Fibrinogen Activity is 200 to 300 mg/dL, against a typical laboratory reference range of 200 to 400 mg/dL. Optimal ranges are FitScript's optimization targets, not diagnostic cut-offs.
For what the marker measures in detail, how it is tested, what moves it and how to read a result, see the dedicated guide on Fibrinogen Activity.
Any result below the reference range is worth discussing with a clinician, and some situations make that conversation more urgent than others. Take a low result forward promptly if you have had a clot in a vein, if a close relative has had an unexplained clot, if you are planning surgery or a long period of reduced mobility, or if you are already on blood thinners and unsure how that affects your result.
Bring context to the appointment rather than just the number. When the sample was drawn, whether you were ill or recovering from surgery, what medications you were on, and what your family history looks like all change how the value is read 4. A clinician will usually want a repeat test on a separate sample before drawing any conclusion 5.
It is equally worth asking what a confirmed result would change. In some people the answer affects decisions around surgery, immobility and family testing. In others it changes very little. That is a reasonable question to put directly to the clinician ordering the test.
This page is educational and is not medical advice. Discuss your results, and any treatment, with a clinician or licensed provider who can see your full history, and seek emergency care for the symptoms listed at the top of this page.
It measures how well your blood can switch off the enzymes that drive clot formation, reported as a percentage of normal activity. It is usually ordered when someone has had an unexplained clot, when clots run in the family, or as part of a broader look at coagulation. A clinician decides whether the test is useful in your situation.
Fasting is not generally required for this test, which is a standard venous blood draw. Follow whatever instructions your lab or clinician gives you, since other markers drawn at the same visit may have their own requirements. Tell the person drawing your blood about any medications you take, because that information affects how the result is read.
No. A single low value is a reason to repeat the test on a separate sample, not a conclusion. Activity can fall temporarily during illness, after surgery, around an active clot or when the sample was handled imperfectly. A clinician looks at the repeat result, the rest of your coagulation markers and your history before deciding anything.
During an active clot, antithrombin is being used up as it does its job, so activity can read low even in someone with a normal baseline. Blood thinners can also shift the measured value in ways that have nothing to do with your inherited level. Never pause or stop a blood thinner to get a cleaner test, that decision belongs to the prescribing clinician.
Values above the reference range are not generally used as a risk marker, and labs regard the test mainly as a way to detect low activity. A clearly normal or high result makes inherited deficiency unlikely, which is often the question the test was asked to answer. It does not rule out every clotting problem, since antithrombin is only one part of the system.
It can be. Inherited forms come from changes in a single gene and typically pass down in a pattern where one altered copy is enough to lower activity. Acquired causes are more common overall, including liver conditions, protein loss through the kidneys and consumption during serious illness. Sorting the two apart takes repeat testing and a clinician's assessment.
The usual next step is a repeat test on a fresh sample taken when you are well, followed by an antigen assay if the low activity is confirmed. Related markers such as the other natural anticoagulants, liver markers and urine protein are often checked to look for an acquired explanation. Where things go from there, including any genetic testing or family testing, is a clinician's decision.
Not by itself. A normal result answers one specific question, whether this particular brake on clotting is working as expected. Clot risk also depends on platelets, clotting factors, the other natural anticoagulants, vessel health and situational factors such as surgery, immobility and injury. Discuss your overall picture with a clinician rather than reading one marker as the whole answer.